| Autor: |
Núñez‐García, Beatriz, Clemente, Mariola Blanco, Sánchez, Juan Cristóbal, Royuela, Ana, Ibargüen, Blanca Cantos Sánchez de, Méndez, Miriam, López‐Ibor, Jorge V., Martínez, Marta, Traseira, Cristina, Garitaonaindia, Yago, Aguado, Ramón, Calvo, Virginia, Torrente, María, Parejo, Consuelo, Provencio, Zaida, Provencio, Mariano |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Aug2023, Vol. 41 Issue 3, p407-414, 8p |
| Abstrakt: |
The high cure rates of Hodgkin lymphoma (HL) make this oncological disease among those with the greatest number of long‐term survivors. This single‐institution study including 383 HL patients with up to 45 years of follow‐up, analyses the morbidity and mortality of this population after treatments in comparison with the overall Spanish population, and investigates whether it has changed over time stratifying by periods of time, as a consequence of therapeutic optimization. The median age was 34.8 years (range 15–87) with median overall survival of 30 years, significantly higher in women (HR 0.58, 95% CI 0.42–0.79) (p = 0.0002). 185 late‐stage diseases were noted (35% patients), cardiovascular disease (CVD) being the most frequent (23.2%). 30% of patients developed at least one second malignant neoplasm (SMN) to give a total of 174 SMNs. 20.9% of the patients died from HL and 67.0% died from non‐HL causes (32.2% from SMN, 17% from CVD). The overall standardized mortality ratio (SMR) was 3.57 (95% CI: 3.0–4.2), with striking values of 7.73 (95% CI: 5.02–8.69) and of 14.75 (95% CI: 11.38–19.12) for women and patients <30 years at diagnosis, respectively. Excluding HL as the cause of death, the SMRs of those diagnosed before 2000 and from 2000 were proved to be similar (3.88 vs 2.73), maintaining in this last period an unacceptable excess of mortality due to secondary toxicity in patients cured of HL. Our study confirm that HL treatment substantially reduces the life expectancy of patients cured of HL. In recent periods, despite therapeutic optimization, deaths from toxicity continue to occur, mainly from CVD and SMN. Risk‐factor monitoring should be intensified, prevention programs developed, and therapeutic optimization of LH investigated, especially in two vulnerable groups: those aged <30 years at diagnosis, and women. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text